Zhao Zihao, Yan Qianqian, Xie Junwei, Liu Zhenjie, Liu Fengxun, Liu Yong, Zhou Sijie, Pan Shaokang, Liu Dongwei, Duan Jiayu, Liu Zhangsuo
Department of Integrated Traditional and Western Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Institute of Nephrology, Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Diabetol Metab Syndr. 2024 Feb 15;16(1):45. doi: 10.1186/s13098-024-01283-2.
Cannabinoid receptors are components of the endocannabinoid system that affect various physiological functions. We aim to investigate the effect of cannabinoid receptor modulation on kidney disease.
PubMed, Web of Science databases, and EMBASE were searched. Articles selection, data extraction and quality assessment were independently performed by two investigators. The SYRCLE's RoB tool was used to assess the risk of study bias, and pooled SMD using a random-effect model and 95% CIs were calculated. Subgroup analyses were conducted in preselected subgroups, and publication bias was evaluated. We compared the effects of CB1 and CB2 antagonists and/or knockout and agonists and/or genetic regulation on renal function, blood glucose levels, body weight, and pathological damage-related indicators in different models of chronic and acute kidney injury.
The blockade or knockout of CB1 could significantly reduce blood urea nitrogen [SMD,- 1.67 (95% CI - 2.27 to - 1.07)], serum creatinine [SMD, - 1.88 (95% CI - 2.91 to - 0.85)], and albuminuria [SMD, - 1.60 (95% CI - 2.16 to - 1.04)] in renal dysfunction animals compared with the control group. The activation of CB2 group could significantly reduce serum creatinine [SMD, - 0.97 (95% CI - 1.83 to - 0.11)] and albuminuria [SMD, - 2.43 (95% CI - 4.63 to - 0.23)] in renal dysfunction animals compared with the control group.
The results suggest that targeting cannabinoid receptors, particularly CB1 antagonists and CB2 agonists, can improve kidney function and reduce inflammatory responses, exerting a renal protective effect and maintaining therapeutic potential in various types of kidney disease.
大麻素受体是内源性大麻素系统的组成部分，可影响多种生理功能。我们旨在研究大麻素受体调节对肾脏疾病的影响。
检索了PubMed、科学网数据库和EMBASE。两名研究人员独立进行文章筛选、数据提取和质量评估。使用SYRCLE的RoB工具评估研究偏倚风险，并计算随机效应模型的合并标准化均数差（SMD）和95%可信区间（CI）。在预先选定的亚组中进行亚组分析，并评估发表偏倚。我们比较了CB1和CB2拮抗剂和/或基因敲除以及激动剂和/或基因调控对不同慢性和急性肾损伤模型中肾功能、血糖水平、体重和病理损伤相关指标的影响。
与对照组相比，CB1的阻断或基因敲除可显著降低肾功能不全动物的血尿素氮[SMD，-1.67（95%CI -2.27至-1.07）]、血清肌酐[SMD，-1.88（95%CI -2.91至-0.85）]和蛋白尿[SMD，-1.60（95%CI -2.16至-1.04）]。与对照组相比，CB2激动剂组可显著降低肾功能不全动物的血清肌酐[SMD，-0.97（95%CI -1.83至-0.11）]和蛋白尿[SMD，-2.43（95%CI -4.63至-0.23）]。
结果表明，靶向大麻素受体，特别是CB1拮抗剂和CB2激动剂，可以改善肾功能并减少炎症反应，在各种类型的肾脏疾病中发挥肾脏保护作用并具有治疗潜力。
